Increase the number of employees to guide the direction of the company and promote the growth strategy as a next-generation CDMO.
To continue its momentum and vision of becoming a next-generation CDMO, KBI Bio-Pharma (KBI), a JSR Life Sciences group company, has recently announced announced the appointment of officers. The company will join Tony Fry as Chief Operating Officer, Shagna Seth as Chief of Staff and Global PMO Leader, Katie Edgar as Senior Vice President of Corporate Strategy and Alliance Management, and Corporate Communications. Four people, Sarah Wakefield, who is the senior vice president in charge.
“We are very pleased to welcome four talented experts to KBI. Each brings unique insights and strong track records to help us navigate the evolving landscape of the industry and create opportunities for success. It is also perfectly aligned with our KBI vision to capture the “We believe all four will play a key role in shaping the future of KBI and ensure that we are the best and most trusted partner to our biopharmaceutical customers around the world. .”
Tony Fry
As KBI’s Chief Operating Officer, Fry brings extensive experience as an operations leader for multiple global pharmaceutical and biotechnology companies. Leveraging her expertise in human resource development, engineering and technical operations, she will strategically guide KBI’s day-to-day operations and support the company’s growth with optimal efficiency. Fry will lead operations teams around the world, including manufacturing, IT and engineering teams. Previously, Fry served as Senior Vice President and General Manager at AGC Biologics, Vice President of Technology Operations at Novartis, and Director of Operations at Boehringer Ingelheim. Throughout his career, Fry has introduced new process development capabilities globally and led a multidisciplinary team that oversees operational safety and compliance. He also implemented a digital strategy to improve technical operations.
Also Read: Fresenius Kabi Launches Plerixafor Injection
Shagna Seth
As KBI’s Chief of Staff, Seth is an experienced business and technology executive who excels at executing operations and driving results. In his new role, Seth will bring more than 20 years of experience in translational research, drug development, manufacturing and program management, applying his expertise in biologics and RNA-based drug development to work with a diverse range of clients. has been successful in collaborating with In addition, Seth’s numerous patents covering a variety of disease areas will make him a productive member of the management team and help establish a world-class PMO. Seth previously served as Interim General Manager and Vice President of Process Development at AGC Biologics.
Katie Edgar
As Senior Vice President of Corporate Strategy and Alliance Management, Edgar will work closely with the KBI and JSR Life Sciences teams to identify strategic growth initiatives and opportunities, improve partnership management and capabilities, and lead the industry. We support the realization of our vision to With a background in strategy and operations, business development, mergers and acquisitions, portfolio and partnership management, Edgar will provide key support in aligning goals across the KBI and JSR networks and will drive KBI’s transformation plans. is.
Sarah Wakefield
As the new Senior Vice President of Corporate Communications, Wakefield brings to KBI 20 years of experience learned in the medical and biotechnology industries. Her expertise lies in building high-performance marketing and communications teams and processes that effectively increase brand awareness, drive incremental revenue, enhance communications and foster an inclusive culture. With a proven track record of success, Wakefield will contribute valuable leadership capabilities in strategic and marketing, branding and identity, DEI initiatives, project management, and organizational and team development.
SOURCE: BusinessWire